

H1 2026 Results Presentation

Christian Mias, CEO | Reinhard Mayer, CFO

The fiscal year 2026 runs from October 2025 to September 2026.

Disclaimer

This presentation has been prepared solely for use at this meeting. This material is given in conjunction with an oral presentation and should not be taken out of context. By attending the meeting where this presentation is held or accessing this presentation, you agree to be bound by the following limitations.

This publication has been prepared by SCHOTT Pharma AG & Co. KGaA. It may contain statements which address such key issues as strategy, future financial results, events, competitive positions and product developments. Such forward-looking statements are subject to a number of risks, uncertainties and other factors, including, but not limited to those described in SCHOTT Pharma's disclosures, in particular in the chapter "Risks" in SCHOTT Pharma's annual report. Should one or more of these risks, uncertainties and other factors materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performances or achievements of SCHOTT Pharma may vary materially from those described in the relevant forward-looking statements.

These statements may be identified by words such as "expect," "want," "anticipate," "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. SCHOTT Pharma neither intends, nor assumes any obligation, to update or revise its forward-looking statements regularly in light of developments which differ from those anticipated. Stated competitive positions are based on management estimates supported by information provided by specialized external agencies.

Our financial reports, presentations, press releases and ad-hoc releases may include alternative financial metrics. These metrics are not defined in the IFRS (International Financial Reporting Standards). SCHOTT Pharma's net assets, financial position and results of operations should not be assessed solely on the basis of these alternative financial metrics. Under no circumstances do they replace the performance indicators presented in the consolidated financial statements and calculated in accordance with the IFRS. The calculation of alternative financial metrics may vary from company to company despite the use of the same terminology. Further information regarding the alternative financial metrics used at SCHOTT Pharma can be found on our web site (<https://www.schott-pharma.com/investor-relations>).

The information contained in this presentation is provided as of the date of this presentation and is subject to change without notice.

Due to rounding, individual numbers presented throughout this, and other documents may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures to which they refer.

For technical reasons, there may be differences in formatting between the accounting records appearing in this document and those published pursuant to legal requirements.



Professional background in a nutshell



Christian Mias

CEO SCHOTT Pharma
since May 1, 2026

Ph.D. in Industrial Engineering,
studied in Berlin and Tokyo

Professional career started at Siemens AG,
focusing on M&A and project management

More than 18 years with SCHOTT,
mainly in international leadership positions in Brazil,
the US, and Germany

Led Tubing plant in Rio de Janeiro;
restructured American plants of Flat Glass

Headed Lighting & Imaging;
most recently in charge of Electronic Packaging, driving global
performance, strategic development, and cultural change



Business Update

Christian Mias, CEO



Ongoing stable development H1 2026



EUR **488**_m

Revenue

(+2.3 % at constant currencies)



EUR **130**_m

EBITDA

(margin of 26.6 %)



56%

HVS revenue share

(+1 percentage point year-over-year)




Expansion of HVS drives profitable growth

Value drivers



Share of revenue with HVS



Strategic importance of HVS

HVS drive growth and margin expansion.


Strategy focuses on addressing pharma trends with innovation.

Continuous increase of HVS revenue share reflects success.



Further strengthening the HVS portfolio with innovations

Latest example: cartriQ® Biopure mitigates systemic risks in packaging of biologics



Financial Update


Reinhard Mayer, CFO



DCS grows dynamically, DDS with temporary headwinds

Revenue¹

EURm



Key developments

Revenue in H1 2026 slightly above prior-year level, reflecting a resilient demand environment.

Drug Containment Solutions (DCS) delivered strong growth, driven by continued high demand for sterile solutions and specialty vials.

Revenues in Drug Delivery Systems (DDS) declined year-on-year due to lower polymer syringe demand.


¹ Segment split excluding consolidation effects, cc = at constant currencies



Strong margin performance in DCS offsets temporary headwinds in DDS

EBITDA¹ and margin

EURm



Key developments

EBITDA in H1 2026 remained at a high level, while the EBITDA margin slightly decreased year-on-year due to temporary effects.

DCS: EBITDA increased disproportionately, driven by strong volume growth and a favorable product mix.

DDS: EBITDA down due to lower utilization and a one-off inventory impairment. Adjusted for the impairment effect, profitability would have been almost on prior-year level, demonstrating the underlying strength of the business.

¹ Segment split excluding consolidation effects, cc = at constant currencies



Further down the P&L...

EURm	H1 2026	H1 2025	Δ yoy
EBIT	86.5	92.9	-6.9%
Financial result	-4.1	-6.5	-36.1%
EBT	82.4	86.4	-4.7%
Income tax expense	-17.9	-18.3	-2.2%
Profit for the period	64.4	68.1	-5.4%
EPS (EUR)	0.43	0.45	-5.4%



Key developments

EBIT -6.9% mainly due to the one-off inventory impairment and higher depreciation as a result of growth investments.

Financial result improved because of lower interest expenses following optimized financing structure.

Income taxes slightly down to EUR 18m, representing an effective tax rate of 21.8%.


Overall, net income decreased 5.4% yoy to EUR 64.4m and earnings per share (EPS) amounted to EUR 0.43.



Significantly higher cash generation driven by working capital improvements

Free cash flow

EURm



Key developments

Operating cash flow benefited from focused working capital management, despite inventory build-up to support future growth.

Cash flow from ongoing investing activities in line with prior year's level at around EUR 50m.

Free cashflow (FCF) more than doubled to EUR 45m.

¹Op. CF = Cash flow from operating activities; ² Inv. CF = Cash flow from ongoing investing activities



FY 2026 guidance confirmed



Revenue growth¹

2% - 5%



EBITDA margin

~27%

Additional information

CAPEX² of EUR 140 – 160m | HVS revenue share on prior year's level

¹At constant currencies; ²Capex excluding leasing



Thank you for your attention

Investor Relations

Tobias.Erfurth@schott.com

Jasko.Terzic@schott.com

Corporate Communications

Katrin.Schreyer@schott.com

Lea.Kaiser@schott.com



Next financial events

Aug 12, 2026:
9M/Q3 2026 results

Dec 10, 2026:
FY/Q4 2026 results

Feb 12, 2027:
Q1 2027 results



Next conference participations

May 19, 2026:
Berenberg
European
Conference
New York

May 27, 2026:
Deutsche Bank
European Champions
Conference
Frankfurt

June 10, 2026:
Citi European
Healthcare Leaders
Conference
London

Sep 22, 2026:
Bank of America
Global Healthcare
Conference
London